Growth Portfolio: Pacific Smiles Group Ltd (ASX: PSQ)
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Overview: Pacific Smiles Group Limited ("Pacific Smiles", "the Company") is an Australian health care company focused on dental services. Pacific Smiles operates a portfolio of dental centres at which independent dentists practice clinical treatments. Revenue is derived from fees charged to dentists for the provision of fully-serviced facilities. The company’s portfolio comprises 54 dental centres across Eastern Australia.
Catalysts: Earnings have consistently increased since 2008 at a compound annual growth rate of 22% per annum. Pacific Smiles is focused on organic growth and in order to maintain momentum, the company targets to open 10 additional centres per year. Management has a strong track record of strategically expanding Pacific Smiles’ portfolio, whilst maintaining a strong balance sheet, a continuation of this trend is the primary catalyst.
Hurdles: The opening of new dental centres is capital intensive and there is no guarantee that new facilities can continue to yield an acceptable return on shareholder funds. 40 percent of centres are less than 3 years old and have yet to demonstrate sustainable earnings potential. With management holding 46 percent of shares outstanding, the potential for minority shareholders to influence corporate governance and strategy is low.
Investment View: Pacific Smiles offers profitable exposure to the domestic healthcare industry. We are attracted to the Company’s growth trajectory, strong balance sheet, and management team. Whilst integration of new practices is a primary risk, the industry’s fragmented nature provides ongoing growth potential. We initiate coverage with a ‘buy’ recommendation for Pacific Smiles’ growth and income potential.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
